Business
Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
Guardant Health Shield multi-cancer detection test selected on basis of strong performance in predicting presence of cancers and cancer tissue of origin
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nGuardant Health Shield multi-cancer detection test selected on basis of strong performance in predicting presence of cancers and cancer tissue of origin\n\n\n\nPilot study by National Cancer Institute’s Cancer Screening Research Network will inform design of future research evaluating use of multi-cancer detection blood tests to screen for cancer\n\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company’s Shield™ multi-cancer detection (MCD) test for use in its Vanguard study, which will address the feasibility of using MCD tests in future clinical trials related to cancer screening. MCD tests are blood tests that can screen for several types of cancers simultaneously.\n\n\nIn February 2024, the National Institutes of Health (NIH) launched the Cancer Screening Research Network (CSRN), which is funded by the NCI, part of NIH, to evaluate emerging cancer screening technologies, including MCD tests. The network will support research to investigate how to identify and diagnose cancers earlier, when they may be easier to treat.\n\n\nAs an initial effort, CSRN is launching the Vanguard Study, a four-year pilot study that will enroll up to 24,000 people to inform the design of a much larger randomized controlled trial evaluating the use of MCD tests for cancer screening. In its studies, the network aims to reach diverse populations, including underserved populations, that are receiving routine care in a variety of health care settings.\n\n\n“Despite recent advances in screening technology, there are still many types of cancer that are difficult to detect with existing technologies until the late stages, when they become much more challenging to treat,” said AmirAli Talasaz, Guardant Health co-CEO. “We are excited about the potential for early detection of multiple cancers through a simple blood draw with our Shield MCD test. The Vanguard study is an important step in demonstrating the value of our technology.”\n\n\nOf the many companies whose tests were evaluated by NCI to be considered for inclusion in the Vanguard study, Guardant Health was selected to be one of two participants, based on the overall performance of its Shield platform. The NCI provided a blinded reference set to verify the pla...